Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2015-01-12 Earnings Release
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
Earnings Release 2015
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates it contains a press release announcing preliminary unaudited financial results for 2014 and guidance for 2015. The document is short (2425 characters) and primarily serves as an announcement of financial results rather than the full financial report itself. It includes a press release as an exhibit but does not contain detailed financial statements or comprehensive analysis. According to the rules, such a document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2015-01-12 English
FORM 4
Director's Dealing
2014-12-29 English
FORM 4
Director's Dealing
2014-12-29 English
FORM 4
Director's Dealing
2014-12-29 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Emergent BioSolutions to the SEC Division of Corporation Finance, referencing prior filings of Form 10-K for the fiscal year ended December 31, 2013, and Form 10-Q for the quarter ended September 30, 2014. The letter confirms an extension of time to respond to the SEC staff's comment letter regarding these filings. The document does not contain any financial data or report content itself but is a correspondence about regulatory filings and timing. It is short (1490 characters) and serves as a regulatory communication rather than a report or announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS).
2014-12-22 English
FORM 4
Director's Dealing
2014-12-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.